论文部分内容阅读
目的观察顺铂等灌注和恩度治疗恶性胸腹积液的临床疗效及安全性。方法 62例晚期恶性胸腹水患者,治疗组32例,胸/腹腔内灌注恩度和化疗药物DDP/5-FU,对照组30例,仅灌注化疗药物DDP/5-FU,均3次/周,连续4周为一疗程,休息4周后,评价疗效及不良反应。结果治疗组中12例CR,16例PR,3例SD,1例PD,有效率为87.5%;对照组6例CR,13例PR,7例SD,4例PD,有效率为63.3%,两组比较差异有统计学意义(P<0.05),不良反应发生率两组比较无统计学意义(P>0.05)。结论顺铂等加恩度灌注治疗恶性胸腹腔积液有较好的疗效和安全性,并有效提高了晚期肿瘤患者的生活质量,值得临床进一步推广应用。
Objective To observe the clinical efficacy and safety of cisplatin infusion and endostar in the treatment of malignant pleural effusion. Methods Sixty-two patients with malignant ascites and pleural effusion were included in the study. Thirty-two patients in the treatment group, 30 patients in the thoracic / intraperitoneal group, and 30 patients in the control group received chemotherapy with DDP / 5-FU, For 4 weeks for a course of treatment, rest for 4 weeks, evaluate the efficacy and adverse reactions. Results In the treatment group, CR was effective in 12 cases of CR, 16 cases of PR, 3 cases of SD and 1 case of PD, and the effective rate was 87.5%. Six cases of CR, 13 cases of PR, 7 cases of SD and 4 cases of PD were 63.3% The difference between the two groups was statistically significant (P <0.05), the incidence of adverse reactions was no significant difference between the two groups (P> 0.05). Conclusions Cisplatin and other Gardner perfusion have good efficacy and safety in the treatment of malignant pleural and peritoneal effusion, and effectively improve the quality of life of patients with advanced cancer. It is worth further clinical application.